Adagene Inc. received China’s NMPA clearance for ADG138’s investigational new drug application, with a first-in-human Phase 1 study in advanced solid tumors expected in the fourth quarter of 2026. The study is designed to assess safety, preliminary efficacy and the recommended dose for Phase 2.

Key Highlights

  • China’s NMPA cleared ADG138’s investigational new drug application for clinical development.
  • ADG138 uses Adagene’s SAFEbody precision masking technology on both binding arms.
  • ADG138’s planned first-in-human Phase 1 study is expected to start in China during the fourth quarter of 2026.
  • The open-label study will evaluate safety and preliminary efficacy in patients with advanced solid tumors and help determine the recommended Phase 2 dose.

ADG138 Moves Toward Human Testing

Adagene Inc. (NASDAQ: ADAG) is classified as a major pharmaceuticals company. The planned Phase 1 study is intended for patients with advanced solid tumors and is expected to start in China during the fourth quarter of 2026. Adagene describes the trial as first-in-human and open-label, with safety and preliminary efficacy among its objectives. The study will also help determine the recommended dose for a Phase 2 programme. ADG138 uses the company’s SAFEbody precision masking technology on both binding arms.

Preclinical Data Included Resistant Tumor Models

The molecule also produced tumor regression in HER2-high and HER2-low models, including a model described as refractory or resistant to Enhertu. Combination testing showed synergistic anti-tumor activity with anti-CTLA-4, anti-PD-1 and anti-CD137 antibodies.